A Relative Bioavailability Study of Valcyte (Valganciclovir) in Lung Transplant Recipients With or Without Cystic Fibrosis.
PHASE1CompletedINTERVENTIONAL
Enrollment
31
Participants
Timeline
Start Date
December 31, 2004
Primary Completion Date
June 30, 2006
Study Completion Date
June 30, 2006
Conditions
Cytomegalovirus Infections
Interventions
DRUG
valganciclovir [Valcyte]
900mg po
Trial Locations (5)
15213
Pittsburgh
27710
Durham
44195
Cleveland
80262
Denver
90033
Los Angeles
All Listed Sponsors
lead
Hoffmann-La Roche
INDUSTRY
NCT00377741 - A Relative Bioavailability Study of Valcyte (Valganciclovir) in Lung Transplant Recipients With or Without Cystic Fibrosis. | Biotech Hunter | Biotech Hunter